Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could poop transplants treat diabetes and heart disease?

NCT ID NCT07421947

Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether fecal microbiota transplantation (FMT) can change the gut microbiome in 30 people with type 2 diabetes and stable coronary artery disease. Participants receive processed stool from healthy donors via colonoscopy. The goal is to see if this alters gut bacteria and possibly improves metabolic and heart health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fecal microbiota transplantation (processed stool from healthy donors given via colonoscopy)
What this could lead to
If successful, this could point toward a new way to treat type 2 diabetes and heart disease by adjusting gut bacteria.
What could go wrong
This is a very small pilot study (30 people) with no control group, so results may not be reliable or generalizable. The procedure carries risks like infection or bowel perforation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Recipients): Age ≥18 years and ≤75 years Diagnosis of type 2 diabetes mellitus Stable coronary artery disease Platelet count ≥50 × 10⁹/L within 2 days prior to FMT Hemoglobin ≥8.5 g/dL within 2 days prior to FMT International normalized ratio (INR) ≤1.5 within 2 days prior to FMT Willingness to undergo fecal microbiota transplantation (FMT) via colonoscopy Signed informed consent Exclusion Criteria (Recipients): Pregnancy or breastfeeding Women of childbearing potential not using adequate contraception Acute coronary syndrome within 12 months Requirement for dual antiplatelet therapy Relevant moderate or severe valvular heart disease Severe kidney dysfunction (estimated GFR \<30 mL/min) Significant liver dysfunction Contraindications to colonoscopy or FMT Systemic steroid or immunosuppressive therapy Antibiotic therapy within 3 months Ongoing infectious disease Active malignancy Participation in another interventional study Life expectancy \<12 months Inability to provide informed consent Inclusion Criteria (Donors): Healthy participants ≥18 years and \<60 years Eligibility for stool donation according to institutional donor screening procedures Negative donor screening results Signed informed consent Exclusion Criteria (Donors): History of gastrointestinal disease History of metabolic, autoimmune, or chronic inflammatory disease History of infectious disease Recent antibiotic therapy High-risk behavior for transmissible diseases Contraindications to colonoscopy Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Inflammation type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Zurich

    Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.